Unique Antibiotic Family

New antibiotics are a massive unmet need. The rise in antibiotic resistant bacteria is ever increasing such that antimicrobial resistance contributed to 5 million death last year, the next pandemic could be bacterial, and there are some conditions for which current antibiotics are ineffective.
Published in Chemistry and Microbiology
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

The rise in death due to antimicrobial resistance is the proverbial 'death by a thousand cuts'. The rise has been slow and steady with antimicrobial resistance now contributing to 5 million deaths per year and rising. Deaths from Covid  are reported at 7 million total since the outbreak of January 2020, although under-reporting has resulted in a central estimate nearer to  25 million deaths. Over the same time period death via antimicrobial resistance and via Covid are near the same number. 

Human nature is weird. It was all hands on deck from all sectors for a rapid Covid outbreak and yet antimicrobial resistance has been met with a collective shrug. Even more weird, a cancer drug that extends the life of a 75 year old for one year can be priced at $100k dollars per year and yet an antibiotic that would save a child from death is expected to be priced at pennies. I get it, cancer is expensive to treat and the additional cost is not a lot compared to the overall treatment cost, while antibiotics have been cheap for forever and a large cost increase would be sticker shock. And yet for some reason saving a child from death is not worth the same price as extending a life by a year - I just don't get the math or the logic.  Beyond this, the next pandemic could be bacterial, would not the best pandemic preparedness be to have a panel of proven antibiotics that are new a novel  ready to distribute? Again, this idea has also been met with a collective shrug.

Even in areas where new antibiotics have an immediate market as current regimens are highly ineffective, such as diabetic foot ulcer infections which lead to 85% of all amputations worldwide,  there is still a reticence to move new antibiotics into the clinic/market. The lifetime risk of diabetic for a foot ulcer is 19% to 34% and this is rising . Morbidity subsequent to a diabetic foot ulcer is high, with a recurrence of 65% at 3–5 years, and shockingly high 5-year mortality rate of 50–70%.

Above are some of the  many reasons the World Health Organization has antimicrobial resistance in its top three risks to the future of human health. Let's hope this new research, and that of others, stops the bleeding.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Structure-Based Drug Design
Physical Sciences > Chemistry > Biological Chemistry > Medicinal Chemistry > Structure-Based Drug Design
Antibiotics
Life Sciences > Biological Sciences > Microbiology > Medical Microbiology > Antimicrobials > Antibiotics

Related Collections

With collections, you can get published faster and increase your visibility.

Biology of rare genetic disorders

This cross-journal Collection between Nature Communications, Communications Biology, npj Genomic Medicine and Scientific Reports brings together research articles that provide new insights into the biology of rare genetic disorders, also known as Mendelian or monogenic disorders.

Publishing Model: Open Access

Deadline: Jan 31, 2025

Clinical trials

In this call for papers, Nature Communications invites submissions of papers reporting interventional trials, including those yielding negative results for which primary end-points were not met.

Publishing Model: Open Access

Deadline: Dec 31, 2024